Gene Editing Patent Application Trends 2025

Gene Editing patent applications in 2025

Error creating thumbnail: File missing

Top Technology Areas in Gene Editing

Top CPC Codes

• C12N9/22 (No explanation available)
  • Count: 79 patents
  • Example: 20250032542. SYSTEMS AND METHODS FOR TRANS-MODULATION OF IMMUNE CELLS BY GENETIC MANIPULATION OF IMMUNE REGULATORY GENES (Targetgene Biotechnologies Ltd.)
• C12N2310/20 (No explanation available)
  • Count: 72 patents
  • Example: 20250032542. SYSTEMS AND METHODS FOR TRANS-MODULATION OF IMMUNE CELLS BY GENETIC MANIPULATION OF IMMUNE REGULATORY GENES (Targetgene Biotechnologies Ltd.)
• C12N15/86 (No explanation available)
  • Count: 43 patents
  • Example: 20250032642. CRISPR-MEDIATED TRANSGENE INSERTION IN NEONATAL CELLS (Regeneron Pharmaceuticals, Inc.)
• C12N15/11 (No explanation available)
  • Count: 41 patents
  • Example: 20250034558. COMPOSITIONS AND METHODS FOR TARGETING, EDITING OR MODIFYING HUMAN GENES (Artisan Development Labs, Inc.)
• C12N2750/14143 (No explanation available)
  • Count: 38 patents
  • Example: 20250032642. CRISPR-MEDIATED TRANSGENE INSERTION IN NEONATAL CELLS (Regeneron Pharmaceuticals, Inc.)
• C12N15/907 (No explanation available)
  • Count: 30 patents
  • Example: 20250032542. SYSTEMS AND METHODS FOR TRANS-MODULATION OF IMMUNE CELLS BY GENETIC MANIPULATION OF IMMUNE REGULATORY GENES (Targetgene Biotechnologies Ltd.)
• C12N15/111 (No explanation available)
  • Count: 30 patents
  • Example: 20250032642. CRISPR-MEDIATED TRANSGENE INSERTION IN NEONATAL CELLS (Regeneron Pharmaceuticals, Inc.)
• A61K48/005 (No explanation available)
  • Count: 16 patents
  • Example: 20250032642. CRISPR-MEDIATED TRANSGENE INSERTION IN NEONATAL CELLS (Regeneron Pharmaceuticals, Inc.)
• C12N2800/80 (No explanation available)
  • Count: 13 patents
  • Example: 20250034582. INCREASING GENE EDITING AND SITE-DIRECTED INTEGRATION EVENTS UTILIZING DEVELOPMENTAL PROMOTERS (Monsanto Technology LLC)
• A61K48/0058 (No explanation available)
  • Count: 13 patents
  • Example: 20250064978. GENE THERAPY METHODS FOR TREATMENT OF DIABETES (Jaguar Gene Therapy, LLC)

Top Companies in Gene Editing 2025

The Regents of the University of California

• Number of Gene Editing patents: 3
• Top CPC codes:
  • C07K16/2809 (No explanation available): 1 patents
  • A61K39/3955 (No explanation available): 1 patents
  • A61K39/4611 (No explanation available): 1 patents
• Recent patents:
  • 20250034251. ANTIBODY CHEMICALLY INDUCED DIMERIZER (ABCID) AS MOLECULAR SWITCHES FOR REGULATING CELLULAR THERAPIES (The Regents of the University of California) (20250130)
  • 20250000945. Suppression of Neurodegeneration with Zinc Transporter Protein 7 (The Regents of the University of California) (20250102)
  • 20250049960. Multicomponent systems for site-specific genome modifications (The Regents of the University of California) (20250213)

EmendoBio Inc.

• Number of Gene Editing patents: 3
• Top CPC codes:
  • C12N9/22 (No explanation available): 3 patents
  • C12N15/11 (No explanation available): 3 patents
  • C12N2310/20 (No explanation available): 3 patents
• Recent patents:
  • 20250034596. Omni-103 CRISPR Nuclease-RNA Complexes (EmendoBio Inc.) (20250130)
  • 20250051741. OMNI-103 CRISPR NUCLEASE (EmendoBio Inc.) (20250213)
  • 20250011740. NOVEL OMNI 117, 140, 150-158, 160-165, 167-177, 180-188, 191-198, 200, 201, 203, 205-209, 211-217, 219, 220, 222, 223, 226, 227, 229, 231-236, 238-245, 247, 250, 254, 256, 257, 260 AND 262 CRISPR NUCLEASES (EmendoBio Inc.) (20250109)

The Trustees of the University of Pennsylvania

• Number of Gene Editing patents: 3
• Top CPC codes:
  • C12N15/86 (No explanation available): 2 patents
  • C12N2750/14143 (No explanation available): 2 patents
  • C12N2830/48 (No explanation available): 2 patents
• Recent patents:
  • 20250041445. GENE THERAPY FOR TREATMENT OF MUCOPOLYSACCHARIDOSIS IIIA (The Trustees of the University of Pennsylvania) (20250206)
  • 20250027900. pH Sensing Technique Based On Graphene Electrodes (The Trustees of the University of Pennsylvania) (20250123)
  • 20250049949. GENE THERAPY FOR LAMIN A-ASSOCIATED DEFICIENCIES (The Trustees of the University of Pennsylvania) (20250213)

CRISPR Therapeutics AG

• Number of Gene Editing patents: 3
• Top CPC codes:
  • C12N9/22 (No explanation available): 3 patents
  • C12N2310/20 (No explanation available): 3 patents
  • A61P3/00 (No explanation available): 2 patents
• Recent patents:
  • 20250043261. METHODS AND COMPOSITIONS FOR TREATING ANGIOPOIETIN-LIKE 3 (ANGPTL3) RELATED CONDITIONS (CRISPR Therapeutics AG) (20250206)
  • 20250027087. MODULATING EXPRESSION OF ALAS1 (5'-AMINOLEVULINATE SYNTHASE 1) GENE (CRISPR Therapeutics AG) (20250123)
  • 20250011743. METHODS AND COMPOSITIONS FOR TREATING ANGIOPOIETIN-LIKE 3 (ANGPTL3) RELATED CONDITIONS (CRISPR Therapeutics AG) (20250109)

SHENZHEN METALENX TECHNOLOGY CO.,LTD

• Number of Gene Editing patents: 3
• Top CPC codes:
  • G01S7/4816 (No explanation available): 1 patents
  • G02B13/0055 (No explanation available): 1 patents
  • G02B13/008 (No explanation available): 1 patents
• Recent patents:
  • 20250044420. LENS FOR ToF (SHENZHEN METALENX TECHNOLOGY CO.,LTD) (20250206)
  • 20250060582. DESIGN METHOD FOR METALENS, METALENS, SHAPING AND BEAM-COMBINATION DEVICE AND DISPLAY DEVICE (SHENZHEN METALENX TECHNOLOGY CO.,LTD) (20250220)
  • 20250063841. METHOD FOR DESIGNING METALENS USED FOR IMAGE SENSOR (SHENZHEN METALENX TECHNOLOGY CO.,LTD) (20250220)

Regeneron Pharmaceuticals, Inc.

• Number of Gene Editing patents: 2
• Top CPC codes:
  • C12N9/22 (No explanation available): 2 patents
  • C12N15/907 (No explanation available): 2 patents
  • C12N2310/20 (No explanation available): 2 patents
• Recent patents:
  • 20250032642. CRISPR-MEDIATED TRANSGENE INSERTION IN NEONATAL CELLS (Regeneron Pharmaceuticals, Inc.) (20250130)
  • 20250002946. Methods And Compositions For Increasing Homology-Directed Repair (Regeneron Pharmaceuticals, Inc.) (20250102)

Monsanto Technology LLC

• Number of Gene Editing patents: 2
• Top CPC codes:
  • C12N15/8213 (No explanation available): 2 patents
  • C12N9/22 (No explanation available): 1 patents
  • C12N15/11 (No explanation available): 1 patents
• Recent patents:
  • 20250034582. INCREASING GENE EDITING AND SITE-DIRECTED INTEGRATION EVENTS UTILIZING DEVELOPMENTAL PROMOTERS (Monsanto Technology LLC) (20250130)
  • 20250027098. METHOD FOR SELECTING TARGET SITES FOR SITE-SPECIFIC GENOME MODIFICATION IN PLANTS (Monsanto Technology LLC) (20250123)

THE BROAD INSTITUTE, INC.

• Number of Gene Editing patents: 2
• Top CPC codes:
  • C12Q1/6823 (No explanation available): 1 patents
  • C12N9/22 (No explanation available): 1 patents
  • C12N15/111 (No explanation available): 1 patents
• Recent patents:
  • 20250034622. SMALL NOVEL CRISPR-CAS SYSTEMS AND METHODS OF USE THEREOF (THE BROAD INSTITUTE, INC.) (20250130)
  • 20250043366. TILED ASSAYS USING CRISPR-CAS BASED DETECTION (THE BROAD INSTITUTE, INC.) (20250206)

Caribou Biosciences, Inc.

• Number of Gene Editing patents: 2
• Top CPC codes:
  • C12Q1/6855 (No explanation available): 1 patents
  • C12N15/11 (No explanation available): 1 patents
  • C07K16/2878 (No explanation available): 1 patents
• Recent patents:
  • 20250034633. A METHOD OF CAPTURING CRISPR ENDONUCLEASE CLEAVAGE PRODUCTS (Caribou Biosciences, Inc.) (20250130)
  • 20250027078. DNA-CONTAINING POLYNUCLEOTIDES AND GUIDES FOR CRISPR TYPE V SYSTEMS, AND METHODS OF MAKING AND USING THE SAME (Caribou Biosciences, Inc.) (20250123)

UCL BUSINESS LTD

• Number of Gene Editing patents: 2
• Top CPC codes:
  • C12N15/86 (No explanation available): 2 patents
  • C12N2750/14143 (No explanation available): 2 patents
  • A61K48/005 (No explanation available): 1 patents
• Recent patents:
  • 20250064974. ENDOGENOUS GENE REGULATION TO TREAT NEUROLOGICAL DISORDERS AND DISEASES (UCL BUSINESS LTD) (20250227)
  • 20250057899. GENE THERAPY FOR CILIOPATHIES (UCL BUSINESS LTD) (20250220)

New Companies in Gene Editing (Last Month)

File:New Companies in Gene Editing Last Month.png

No new companies detected in the last month.

Emerging Technology Areas in Gene Editing

• G06T2207/20212 (No explanation available)
  • Count: 1 patents
  • Example: 20250016295. CAMERA MODULE WITH CHROMATIC ABERRATION CORRECTION (Meta Platforms Technologies, LLC)
• G06T2207/10024 (No explanation available)
  • Count: 1 patents
  • Example: 20250016295. CAMERA MODULE WITH CHROMATIC ABERRATION CORRECTION (Meta Platforms Technologies, LLC)
• H04N23/16 (No explanation available)
  • Count: 1 patents
  • Example: 20250016295. CAMERA MODULE WITH CHROMATIC ABERRATION CORRECTION (Meta Platforms Technologies, LLC)
• G06T7/80 (No explanation available)
  • Count: 1 patents
  • Example: 20250016295. CAMERA MODULE WITH CHROMATIC ABERRATION CORRECTION (Meta Platforms Technologies, LLC)
• G06T5/80 (No explanation available)
  • Count: 1 patents
  • Example: 20250016295. CAMERA MODULE WITH CHROMATIC ABERRATION CORRECTION (Meta Platforms Technologies, LLC)
• G06T5/50 (No explanation available)
  • Count: 1 patents
  • Example: 20250016295. CAMERA MODULE WITH CHROMATIC ABERRATION CORRECTION (Meta Platforms Technologies, LLC)
• G02B27/141 (No explanation available)
  • Count: 1 patents
  • Example: 20250016295. CAMERA MODULE WITH CHROMATIC ABERRATION CORRECTION (Meta Platforms Technologies, LLC)
• H04N9/646 (No explanation available)
  • Count: 1 patents
  • Example: 20250016295. CAMERA MODULE WITH CHROMATIC ABERRATION CORRECTION (Meta Platforms Technologies, LLC)
• B82Y30/00 (No explanation available)
  • Count: 1 patents
  • Example: 20250015474. METALENS (FUJIFILM Corporation)
• H01P3/20 (No explanation available)
  • Count: 1 patents
  • Example: 20250015474. METALENS (FUJIFILM Corporation)

Top Companies in Emerging Gene Editing Technologies 2025

• Meta Platforms Technologies, LLC: 8 patents
• FUJIFILM Corporation: 2 patents

Top Inventors in Gene Editing

Chenglong HAO

• Number of Gene Editing patents: 3
• Top companies:
  • SHENZHEN METALENX TECHNOLOGY CO.,LTD: 3 patents
• Recent patents:
  • 20250044420. LENS FOR ToF (SHENZHEN METALENX TECHNOLOGY CO.,LTD) (20250206)
  • 20250060582. DESIGN METHOD FOR METALENS, METALENS, SHAPING AND BEAM-COMBINATION DEVICE AND DISPLAY DEVICE (SHENZHEN METALENX TECHNOLOGY CO.,LTD) (20250220)
  • 20250063841. METHOD FOR DESIGNING METALENS USED FOR IMAGE SENSOR (SHENZHEN METALENX TECHNOLOGY CO.,LTD) (20250220)

Fengze TAN

• Number of Gene Editing patents: 3
• Top companies:
  • SHENZHEN METALENX TECHNOLOGY CO.,LTD: 3 patents
• Recent patents:
  • 20250044420. LENS FOR ToF (SHENZHEN METALENX TECHNOLOGY CO.,LTD) (20250206)
  • 20250060582. DESIGN METHOD FOR METALENS, METALENS, SHAPING AND BEAM-COMBINATION DEVICE AND DISPLAY DEVICE (SHENZHEN METALENX TECHNOLOGY CO.,LTD) (20250220)
  • 20250063841. METHOD FOR DESIGNING METALENS USED FOR IMAGE SENSOR (SHENZHEN METALENX TECHNOLOGY CO.,LTD) (20250220)

Jian ZHU

• Number of Gene Editing patents: 3
• Top companies:
  • SHENZHEN METALENX TECHNOLOGY CO.,LTD: 3 patents
• Recent patents:
  • 20250044420. LENS FOR ToF (SHENZHEN METALENX TECHNOLOGY CO.,LTD) (20250206)
  • 20250060582. DESIGN METHOD FOR METALENS, METALENS, SHAPING AND BEAM-COMBINATION DEVICE AND DISPLAY DEVICE (SHENZHEN METALENX TECHNOLOGY CO.,LTD) (20250220)
  • 20250063841. METHOD FOR DESIGNING METALENS USED FOR IMAGE SENSOR (SHENZHEN METALENX TECHNOLOGY CO.,LTD) (20250220)

Leida Rassouli-Taylor of Philadelphia PA (US)

• Number of Gene Editing patents: 2
• Top companies:
  • Amicus Therapeutics, Inc: 1 patents
  • The Trustees of the University of Pennsylvania: 1 patents
• Recent patents:
  • 20250034533. Compositions And Methods For Treating Mucopolysaccharidosis IIIA (Amicus Therapeutics, Inc) (20250130)
  • 20250041445. GENE THERAPY FOR TREATMENT OF MUCOPOLYSACCHARIDOSIS IIIA (The Trustees of the University of Pennsylvania) (20250206)

Lior IZHAR

• Number of Gene Editing patents: 2
• Top companies:
  • EmendoBio Inc.: 1 patents
  • EMENDOBIO INC: 1 patents
• Recent patents:
  • 20250034596. Omni-103 CRISPR Nuclease-RNA Complexes (EmendoBio Inc.) (20250130)
  • [[20250011741. OMNI 263, 264, 266, 268, 269, 271, 274, 275, 276, 278, 279, 280, 281, 283, 284, 286, 287, 288, 290, 291, 293, 294, 295, 296, 297, 298, 299, 300, 301, 302, 303, 304, 305, 307, 308, 309, 310, 311, 312, 313, 314, 315, 316, 317, 318, 319, 320, 321, 322, 323, 324, 325, 326, 327, 329, 330, 331, 332, 333, 334, 336, 337, 338, 339, 340, 341, 342, 343, 344, 345, 346, 347, 348, 349, 350, 351, 352, 353, 354, 356, 357, 358, 359, 360, 361, 362, 363, 364, 365, 366, 367, 368, 369, 370, 371, 372, 373, 375, 376, (EMENDOBIO INC)]] (20250109)

Liat ROCKAH

• Number of Gene Editing patents: 2
• Top companies:
  • EmendoBio Inc.: 1 patents
  • EMENDOBIO INC: 1 patents
• Recent patents:
  • 20250034596. Omni-103 CRISPR Nuclease-RNA Complexes (EmendoBio Inc.) (20250130)
  • [[20250011741. OMNI 263, 264, 266, 268, 269, 271, 274, 275, 276, 278, 279, 280, 281, 283, 284, 286, 287, 288, 290, 291, 293, 294, 295, 296, 297, 298, 299, 300, 301, 302, 303, 304, 305, 307, 308, 309, 310, 311, 312, 313, 314, 315, 316, 317, 318, 319, 320, 321, 322, 323, 324, 325, 326, 327, 329, 330, 331, 332, 333, 334, 336, 337, 338, 339, 340, 341, 342, 343, 344, 345, 346, 347, 348, 349, 350, 351, 352, 353, 354, 356, 357, 358, 359, 360, 361, 362, 363, 364, 365, 366, 367, 368, 369, 370, 371, 372, 373, 375, 376, (EMENDOBIO INC)]] (20250109)

Nir HECHT

• Number of Gene Editing patents: 2
• Top companies:
  • EmendoBio Inc.: 1 patents
  • EMENDOBIO INC: 1 patents
• Recent patents:
  • 20250034596. Omni-103 CRISPR Nuclease-RNA Complexes (EmendoBio Inc.) (20250130)
  • [[20250011741. OMNI 263, 264, 266, 268, 269, 271, 274, 275, 276, 278, 279, 280, 281, 283, 284, 286, 287, 288, 290, 291, 293, 294, 295, 296, 297, 298, 299, 300, 301, 302, 303, 304, 305, 307, 308, 309, 310, 311, 312, 313, 314, 315, 316, 317, 318, 319, 320, 321, 322, 323, 324, 325, 326, 327, 329, 330, 331, 332, 333, 334, 336, 337, 338, 339, 340, 341, 342, 343, 344, 345, 346, 347, 348, 349, 350, 351, 352, 353, 354, 356, 357, 358, 359, 360, 361, 362, 363, 364, 365, 366, 367, 368, 369, 370, 371, 372, 373, 375, 376, (EMENDOBIO INC)]] (20250109)

Alexandra Briner Crawley of Cary NC (US)

• Number of Gene Editing patents: 2
• Top companies:
  • LifeEDIT Therapeutics, Inc.: 2 patents
• Recent patents:
  • 20250066783. POLYPEPTIDES USEFUL FOR GENE EDITING AND METHODS OF USE (LifeEDIT Therapeutics, Inc.) (20250227)
  • 20250043315. RNA-GUIDED NUCLEASES AND ACTIVE FRAGMENTS AND VARIANTS THEREOF AND METHODS OF USE (LifeEDIT Therapeutics, Inc.) (20250206)

Tedd D. Elich of Durham NC (US)

• Number of Gene Editing patents: 2
• Top companies:
  • LifeEDIT Therapeutics, Inc.: 2 patents
• Recent patents:
  • 20250066783. POLYPEPTIDES USEFUL FOR GENE EDITING AND METHODS OF USE (LifeEDIT Therapeutics, Inc.) (20250227)
  • 20250043315. RNA-GUIDED NUCLEASES AND ACTIVE FRAGMENTS AND VARIANTS THEREOF AND METHODS OF USE (LifeEDIT Therapeutics, Inc.) (20250206)

Eric B. Kmiec of Middletown DE (US)

• Number of Gene Editing patents: 2
• Top companies:
  • Christiana Care Gene Editing Institute, Inc.: 2 patents
• Recent patents:
  • 20250001010. NRAS GENE KNOCKOUT FOR TREATMENT OF CANCER (Christiana Care Gene Editing Institute, Inc.) (20250102)
  • 20250018060. ADENOVIRUS DELIVERY SYSTEM FOR CANCER TREATMENT (Christiana Care Gene Editing Institute, Inc.) (20250116)

Kelly H. Banas of Bear DE (US)

• Number of Gene Editing patents: 2
• Top companies:
  • Christiana Care Gene Editing Institute, Inc.: 2 patents
• Recent patents:
  • 20250001010. NRAS GENE KNOCKOUT FOR TREATMENT OF CANCER (Christiana Care Gene Editing Institute, Inc.) (20250102)
  • 20250018060. ADENOVIRUS DELIVERY SYSTEM FOR CANCER TREATMENT (Christiana Care Gene Editing Institute, Inc.) (20250116)

Joseph J. HIGGINS of Lexington MA (US)

• Number of Gene Editing patents: 2
• Top companies:
  • Saliogen Therapeutics, Inc.: 2 patents
• Recent patents:
  • 20250002876. MOBILE ELEMENTS AND CHIMERIC CONSTRUCTS THEREOF (Saliogen Therapeutics, Inc.) (20250102)
  • 20250011736. TRANSPOSABLE MOBILE ELEMENTS WITH ENHANCED GENOMIC SITE SELECTION (Saliogen Therapeutics, Inc.) (20250109)

Nancy CRAIG of Lexington MA (US)

• Number of Gene Editing patents: 2
• Top companies:
  • Saliogen Therapeutics, Inc.: 2 patents
• Recent patents:
  • 20250002876. MOBILE ELEMENTS AND CHIMERIC CONSTRUCTS THEREOF (Saliogen Therapeutics, Inc.) (20250102)
  • 20250011736. TRANSPOSABLE MOBILE ELEMENTS WITH ENHANCED GENOMIC SITE SELECTION (Saliogen Therapeutics, Inc.) (20250109)

Christopher BROWN of Albany CA (US)

• Number of Gene Editing patents: 2
• Top companies:
  • Metagenomi, Inc.: 1 patents
  • METAGENOMI, INC.: 1 patents
• Recent patents:
  • 20250002881. CLASS II, TYPE V CRISPR SYSTEMS (Metagenomi, Inc.) (20250102)
  • 20250059568. CLASS II, TYPE V CRISPR SYSTEMS (METAGENOMI, INC.) (20250220)

Cindy CASTELLE of San Francisco CA (US)

• Number of Gene Editing patents: 2
• Top companies:
  • Metagenomi, Inc.: 1 patents
  • METAGENOMI, INC.: 1 patents
• Recent patents:
  • 20250002881. CLASS II, TYPE V CRISPR SYSTEMS (Metagenomi, Inc.) (20250102)
  • 20250059568. CLASS II, TYPE V CRISPR SYSTEMS (METAGENOMI, INC.) (20250220)

Lisa ALEXANDER of Albany CA (US)

• Number of Gene Editing patents: 2
• Top companies:
  • Metagenomi, Inc.: 1 patents
  • METAGENOMI, INC.: 1 patents
• Recent patents:
  • 20250002881. CLASS II, TYPE V CRISPR SYSTEMS (Metagenomi, Inc.) (20250102)
  • 20250059568. CLASS II, TYPE V CRISPR SYSTEMS (METAGENOMI, INC.) (20250220)

Yi-Shan Chen of South Boston MA (US)

• Number of Gene Editing patents: 2
• Top companies:
  • CRISPR Therapeutics AG: 2 patents
• Recent patents:
  • 20250043261. METHODS AND COMPOSITIONS FOR TREATING ANGIOPOIETIN-LIKE 3 (ANGPTL3) RELATED CONDITIONS (CRISPR Therapeutics AG) (20250206)
  • 20250011743. METHODS AND COMPOSITIONS FOR TREATING ANGIOPOIETIN-LIKE 3 (ANGPTL3) RELATED CONDITIONS (CRISPR Therapeutics AG) (20250109)

Sandeep Soni of South Boston CA (US)

• Number of Gene Editing patents: 2
• Top companies:
  • CRISPR Therapeutics AG: 2 patents
• Recent patents:
  • 20250043261. METHODS AND COMPOSITIONS FOR TREATING ANGIOPOIETIN-LIKE 3 (ANGPTL3) RELATED CONDITIONS (CRISPR Therapeutics AG) (20250206)
  • 20250011743. METHODS AND COMPOSITIONS FOR TREATING ANGIOPOIETIN-LIKE 3 (ANGPTL3) RELATED CONDITIONS (CRISPR Therapeutics AG) (20250109)

Laura Serwer of South Boston MA (US)

• Number of Gene Editing patents: 2
• Top companies:
  • CRISPR Therapeutics AG: 2 patents
• Recent patents:
  • 20250043261. METHODS AND COMPOSITIONS FOR TREATING ANGIOPOIETIN-LIKE 3 (ANGPTL3) RELATED CONDITIONS (CRISPR Therapeutics AG) (20250206)
  • 20250011743. METHODS AND COMPOSITIONS FOR TREATING ANGIOPOIETIN-LIKE 3 (ANGPTL3) RELATED CONDITIONS (CRISPR Therapeutics AG) (20250109)

Jonathan Terrett of South Boston MA (US)

• Number of Gene Editing patents: 2
• Top companies:
  • CRISPR Therapeutics AG: 2 patents
• Recent patents:
  • 20250043261. METHODS AND COMPOSITIONS FOR TREATING ANGIOPOIETIN-LIKE 3 (ANGPTL3) RELATED CONDITIONS (CRISPR Therapeutics AG) (20250206)
  • 20250011743. METHODS AND COMPOSITIONS FOR TREATING ANGIOPOIETIN-LIKE 3 (ANGPTL3) RELATED CONDITIONS (CRISPR Therapeutics AG) (20250109)

John Kulman of South Boston MA (US)

• Number of Gene Editing patents: 2
• Top companies:
  • CRISPR Therapeutics AG: 2 patents
• Recent patents:
  • 20250043261. METHODS AND COMPOSITIONS FOR TREATING ANGIOPOIETIN-LIKE 3 (ANGPTL3) RELATED CONDITIONS (CRISPR Therapeutics AG) (20250206)
  • 20250011743. METHODS AND COMPOSITIONS FOR TREATING ANGIOPOIETIN-LIKE 3 (ANGPTL3) RELATED CONDITIONS (CRISPR Therapeutics AG) (20250109)

Benjamin OAKES of El Cerrito CA (US)

• Number of Gene Editing patents: 2
• Top companies:
  • Scribe Therapeutics Inc.: 2 patents
• Recent patents:
  • 20250043262. GENE EDITING PAIRS (Scribe Therapeutics Inc.) (20250206)
  • 20250011756. METHODS OF EDITING WITH ENGINEERED CLASS 2 TYPE V CRISPR SYSTEMS (Scribe Therapeutics Inc.) (20250109)

Sean HIGGINS of Alameda CA (US)

• Number of Gene Editing patents: 2
• Top companies:
  • Scribe Therapeutics Inc.: 2 patents
• Recent patents:
  • 20250043262. GENE EDITING PAIRS (Scribe Therapeutics Inc.) (20250206)
  • 20250011756. METHODS OF EDITING WITH ENGINEERED CLASS 2 TYPE V CRISPR SYSTEMS (Scribe Therapeutics Inc.) (20250109)

Sarah DENNY of San Francisco CA (US)

• Number of Gene Editing patents: 2
• Top companies:
  • Scribe Therapeutics Inc.: 2 patents
• Recent patents:
  • 20250043262. GENE EDITING PAIRS (Scribe Therapeutics Inc.) (20250206)
  • 20250011756. METHODS OF EDITING WITH ENGINEERED CLASS 2 TYPE V CRISPR SYSTEMS (Scribe Therapeutics Inc.) (20250109)

Brett T. STAAHL of Tiburon CA (US)

• Number of Gene Editing patents: 2
• Top companies:
  • Scribe Therapeutics Inc.: 2 patents
• Recent patents:
  • 20250043262. GENE EDITING PAIRS (Scribe Therapeutics Inc.) (20250206)
  • 20250011756. METHODS OF EDITING WITH ENGINEERED CLASS 2 TYPE V CRISPR SYSTEMS (Scribe Therapeutics Inc.) (20250109)

Isabel COLIN of Oakland CA (US)

• Number of Gene Editing patents: 2
• Top companies:
  • Scribe Therapeutics Inc.: 2 patents
• Recent patents:
  • 20250043262. GENE EDITING PAIRS (Scribe Therapeutics Inc.) (20250206)
  • 20250011756. METHODS OF EDITING WITH ENGINEERED CLASS 2 TYPE V CRISPR SYSTEMS (Scribe Therapeutics Inc.) (20250109)

Edwin Neumann of Somerville MA (US)

• Number of Gene Editing patents: 2
• Top companies:
  • Whitehead Institute for Biomedical Research: 2 patents
• Recent patents:
  • 20250019673. Compositions and Methods for Making Epigenetic Modifications (Whitehead Institute for Biomedical Research) (20250116)
  • 20250027059. Compositions and Methods for Making Epigenetic Modifications (Whitehead Institute for Biomedical Research) (20250123)

Tessa Bertozzi of Cambridge MA (US)

• Number of Gene Editing patents: 2
• Top companies:
  • Whitehead Institute for Biomedical Research: 2 patents
• Recent patents:
  • 20250019673. Compositions and Methods for Making Epigenetic Modifications (Whitehead Institute for Biomedical Research) (20250116)
  • 20250027059. Compositions and Methods for Making Epigenetic Modifications (Whitehead Institute for Biomedical Research) (20250123)

Jonathan Weissman of Cambridge MA (US)

• Number of Gene Editing patents: 2
• Top companies:
  • Whitehead Institute for Biomedical Research: 2 patents
• Recent patents:
  • 20250019673. Compositions and Methods for Making Epigenetic Modifications (Whitehead Institute for Biomedical Research) (20250116)
  • 20250027059. Compositions and Methods for Making Epigenetic Modifications (Whitehead Institute for Biomedical Research) (20250123)

Jesse Salk of Seattle WA (US)

• Number of Gene Editing patents: 2
• Top companies:
  • UNIVERSITY OF WASHINGTON THROUGH ITS CENTER FOR COMMERCIALIZATION: 2 patents
• Recent patents:
  • 20250019761. METHODS OF LOWERING THE ERROR RATE OF MASSIVELY PARALLEL DNA SEQUENCING USING DUPLEX CONSENSUS SEQUENCING (UNIVERSITY OF WASHINGTON THROUGH ITS CENTER FOR COMMERCIALIZATION) (20250116)
  • 20250011866. METHODS OF LOWERING THE ERROR RATE OF MASSIVELY PARALLEL DNA SEQUENCING USING DUPLEX CONSENSUS SEQUENCING (UNIVERSITY OF WASHINGTON THROUGH ITS CENTER FOR COMMERCIALIZATION) (20250109)

Lawrence A. Loeb of Bellevue WA (US)

• Number of Gene Editing patents: 2
• Top companies:
  • UNIVERSITY OF WASHINGTON THROUGH ITS CENTER FOR COMMERCIALIZATION: 2 patents
• Recent patents:
  • 20250019761. METHODS OF LOWERING THE ERROR RATE OF MASSIVELY PARALLEL DNA SEQUENCING USING DUPLEX CONSENSUS SEQUENCING (UNIVERSITY OF WASHINGTON THROUGH ITS CENTER FOR COMMERCIALIZATION) (20250116)
  • 20250011866. METHODS OF LOWERING THE ERROR RATE OF MASSIVELY PARALLEL DNA SEQUENCING USING DUPLEX CONSENSUS SEQUENCING (UNIVERSITY OF WASHINGTON THROUGH ITS CENTER FOR COMMERCIALIZATION) (20250109)

Michael Schmitt of Seattle WA (US)

• Number of Gene Editing patents: 2
• Top companies:
  • UNIVERSITY OF WASHINGTON THROUGH ITS CENTER FOR COMMERCIALIZATION: 2 patents
• Recent patents:
  • 20250019761. METHODS OF LOWERING THE ERROR RATE OF MASSIVELY PARALLEL DNA SEQUENCING USING DUPLEX CONSENSUS SEQUENCING (UNIVERSITY OF WASHINGTON THROUGH ITS CENTER FOR COMMERCIALIZATION) (20250116)
  • 20250011866. METHODS OF LOWERING THE ERROR RATE OF MASSIVELY PARALLEL DNA SEQUENCING USING DUPLEX CONSENSUS SEQUENCING (UNIVERSITY OF WASHINGTON THROUGH ITS CENTER FOR COMMERCIALIZATION) (20250109)

Lior Izhar

• Number of Gene Editing patents: 2
• Top companies:
  • EmendoBio Inc.: 2 patents
• Recent patents:
  • 20250051741. OMNI-103 CRISPR NUCLEASE (EmendoBio Inc.) (20250213)
  • 20250011740. NOVEL OMNI 117, 140, 150-158, 160-165, 167-177, 180-188, 191-198, 200, 201, 203, 205-209, 211-217, 219, 220, 222, 223, 226, 227, 229, 231-236, 238-245, 247, 250, 254, 256, 257, 260 AND 262 CRISPR NUCLEASES (EmendoBio Inc.) (20250109)

Nadav Marbach Bar

• Number of Gene Editing patents: 2
• Top companies:
  • EmendoBio Inc.: 2 patents
• Recent patents:
  • 20250051741. OMNI-103 CRISPR NUCLEASE (EmendoBio Inc.) (20250213)
  • 20250011740. NOVEL OMNI 117, 140, 150-158, 160-165, 167-177, 180-188, 191-198, 200, 201, 203, 205-209, 211-217, 219, 220, 222, 223, 226, 227, 229, 231-236, 238-245, 247, 250, 254, 256, 257, 260 AND 262 CRISPR NUCLEASES (EmendoBio Inc.) (20250109)

Liat Rockah

• Number of Gene Editing patents: 2
• Top companies:
  • EmendoBio Inc.: 2 patents
• Recent patents:
  • 20250051741. OMNI-103 CRISPR NUCLEASE (EmendoBio Inc.) (20250213)
  • 20250011740. NOVEL OMNI 117, 140, 150-158, 160-165, 167-177, 180-188, 191-198, 200, 201, 203, 205-209, 211-217, 219, 220, 222, 223, 226, 227, 229, 231-236, 238-245, 247, 250, 254, 256, 257, 260 AND 262 CRISPR NUCLEASES (EmendoBio Inc.) (20250109)

Nurit Meron

• Number of Gene Editing patents: 2
• Top companies:
  • EmendoBio Inc.: 2 patents
• Recent patents:
  • 20250051741. OMNI-103 CRISPR NUCLEASE (EmendoBio Inc.) (20250213)
  • 20250011740. NOVEL OMNI 117, 140, 150-158, 160-165, 167-177, 180-188, 191-198, 200, 201, 203, 205-209, 211-217, 219, 220, 222, 223, 226, 227, 229, 231-236, 238-245, 247, 250, 254, 256, 257, 260 AND 262 CRISPR NUCLEASES (EmendoBio Inc.) (20250109)

Ophir Adiv Tal

• Number of Gene Editing patents: 2
• Top companies:
  • EmendoBio Inc.: 2 patents
• Recent patents:
  • 20250051741. OMNI-103 CRISPR NUCLEASE (EmendoBio Inc.) (20250213)
  • 20250011740. NOVEL OMNI 117, 140, 150-158, 160-165, 167-177, 180-188, 191-198, 200, 201, 203, 205-209, 211-217, 219, 220, 222, 223, 226, 227, 229, 231-236, 238-245, 247, 250, 254, 256, 257, 260 AND 262 CRISPR NUCLEASES (EmendoBio Inc.) (20250109)

Ariel Gispan

• Number of Gene Editing patents: 2
• Top companies:
  • EmendoBio Inc.: 2 patents
• Recent patents:
  • 20250051741. OMNI-103 CRISPR NUCLEASE (EmendoBio Inc.) (20250213)
  • 20250011740. NOVEL OMNI 117, 140, 150-158, 160-165, 167-177, 180-188, 191-198, 200, 201, 203, 205-209, 211-217, 219, 220, 222, 223, 226, 227, 229, 231-236, 238-245, 247, 250, 254, 256, 257, 260 AND 262 CRISPR NUCLEASES (EmendoBio Inc.) (20250109)

Idit Buch

• Number of Gene Editing patents: 2
• Top companies:
  • EmendoBio Inc.: 2 patents
• Recent patents:
  • 20250051741. OMNI-103 CRISPR NUCLEASE (EmendoBio Inc.) (20250213)
  • 20250011740. NOVEL OMNI 117, 140, 150-158, 160-165, 167-177, 180-188, 191-198, 200, 201, 203, 205-209, 211-217, 219, 220, 222, 223, 226, 227, 229, 231-236, 238-245, 247, 250, 254, 256, 257, 260 AND 262 CRISPR NUCLEASES (EmendoBio Inc.) (20250109)

Abdoulaye Ndao of Brookline MA (US)

• Number of Gene Editing patents: 2
• Top companies:
  • Imagia, Inc.: 2 patents
• Recent patents:
  • 20250052925. Frequency-Selective Optical Metalens Filters (Imagia, Inc.) (20250213)
  • 20250012944. Optical Metalens Systems and Methods of Manufacture (Imagia, Inc.) (20250109)

Dan Michael WEINTHAL

• Number of Gene Editing patents: 1
• Top companies:
  • Targetgene Biotechnologies Ltd.: 1 patents
• Recent patents:
  • 20250032542. SYSTEMS AND METHODS FOR TRANS-MODULATION OF IMMUNE CELLS BY GENETIC MANIPULATION OF IMMUNE REGULATORY GENES (Targetgene Biotechnologies Ltd.) (20250130)

Yoel Moshe SHIBOLETH

• Number of Gene Editing patents: 1
• Top companies:
  • Targetgene Biotechnologies Ltd.: 1 patents
• Recent patents:
  • 20250032542. SYSTEMS AND METHODS FOR TRANS-MODULATION OF IMMUNE CELLS BY GENETIC MANIPULATION OF IMMUNE REGULATORY GENES (Targetgene Biotechnologies Ltd.) (20250130)

David STEINER

• Number of Gene Editing patents: 1
• Top companies:
  • Targetgene Biotechnologies Ltd.: 1 patents
• Recent patents:
  • 20250032542. SYSTEMS AND METHODS FOR TRANS-MODULATION OF IMMUNE CELLS BY GENETIC MANIPULATION OF IMMUNE REGULATORY GENES (Targetgene Biotechnologies Ltd.) (20250130)

Talya KUNIK

• Number of Gene Editing patents: 1
• Top companies:
  • Targetgene Biotechnologies Ltd.: 1 patents
• Recent patents:
  • 20250032542. SYSTEMS AND METHODS FOR TRANS-MODULATION OF IMMUNE CELLS BY GENETIC MANIPULATION OF IMMUNE REGULATORY GENES (Targetgene Biotechnologies Ltd.) (20250130)

Khalid SHAH of Andover MA (US)

• Number of Gene Editing patents: 1
• Top companies:
  • THE BRIGHAM AND WOMEN'S HOSPITAL, INC.: 1 patents
• Recent patents:
  • 20250032611. GENE EDITING AND ENGINEERING STEM CELLS FOR DRUG DELIVERY (THE BRIGHAM AND WOMEN'S HOSPITAL, INC.) (20250130)

Andrew Baik of Scarsdale NY (US)

• Number of Gene Editing patents: 1
• Top companies:
  • Regeneron Pharmaceuticals, Inc.: 1 patents
• Recent patents:
  • 20250032642. CRISPR-MEDIATED TRANSGENE INSERTION IN NEONATAL CELLS (Regeneron Pharmaceuticals, Inc.) (20250130)

Katherine Cygnar of New York NY (US)

• Number of Gene Editing patents: 1
• Top companies:
  • Regeneron Pharmaceuticals, Inc.: 1 patents
• Recent patents:
  • 20250032642. CRISPR-MEDIATED TRANSGENE INSERTION IN NEONATAL CELLS (Regeneron Pharmaceuticals, Inc.) (20250130)

Leah Sabin of Goldens Bridge NY (US)

• Number of Gene Editing patents: 1
• Top companies:
  • Regeneron Pharmaceuticals, Inc.: 1 patents
• Recent patents:
  • 20250032642. CRISPR-MEDIATED TRANSGENE INSERTION IN NEONATAL CELLS (Regeneron Pharmaceuticals, Inc.) (20250130)

Poulami Samai of New York NY (US)

• Number of Gene Editing patents: 1
• Top companies:
  • Regeneron Pharmaceuticals, Inc.: 1 patents
• Recent patents:
  • 20250032642. CRISPR-MEDIATED TRANSGENE INSERTION IN NEONATAL CELLS (Regeneron Pharmaceuticals, Inc.) (20250130)

Philip Calafati of Cambridge MA (US)

• Number of Gene Editing patents: 1
• Top companies:
  • Regeneron Pharmaceuticals, Inc.: 1 patents
• Recent patents:
  • 20250032642. CRISPR-MEDIATED TRANSGENE INSERTION IN NEONATAL CELLS (Regeneron Pharmaceuticals, Inc.) (20250130)

Top Collaborations in Gene Editing

Top US States for Gene Editing Inventors

Top Cities for Gene Editing Inventors

• Cambridge: 28 inventors
• Shanghai: 19 inventors
• San Francisco: 17 inventors
• Philadelphia: 17 inventors
• South Boston: 17 inventors
• Shenzhen: 13 inventors
• Pleasanton: 12 inventors
• Qingdao: 12 inventors
• New York: 11 inventors
• Berkeley: 11 inventors
• Oakland: 11 inventors
• Boston: 10 inventors
• Rehovot: 9 inventors
• London: 9 inventors
• San Diego: 8 inventors
• Beijing: 8 inventors
• Worcester: 7 inventors
• CAMBRIDGE: 7 inventors
• St. Louis: 7 inventors
• Tel Aviv: 7 inventors